Ventyx Biosciences (VTYX) Jefferies Global Healthcare Conference summary

NLRP3 program overview and differentiation

• CNS-penetrant NLRP3 inhibitor demonstrated best-in-class safety and PK/PD profile in phase I, achieving complete IL-1β signaling suppression at low doses in both blood and CSF.

• Downstream effects on key biomarkers (IL-6, hsCRP, fibrinogen) were observed, supporting robust control of NLRP3-driven pathways.

• Phase IIa study in Parkinson's disease is planned for early second half of the year, leveraging nonclinical data linking NLRP3 to neurodegeneration.

Preclinical obesity studies and combination data

• Two internally controlled mouse studies showed significant weight loss and improved metabolic parameters with NLRP3 inhibition, both as monotherapy and in combination with semaglutide.

• Combination therapy produced additive benefits, including further weight loss and protection of lean mass, confirmed by both DEXA imaging and dissection.

• Data consistency and tightness were highlighted, with 20 animals per group and strong statistical significance.

• The combination study is the first to show NLRP3 inhibitor with GLP-1, demonstrating incremental biomarker and weight loss benefits without added tolerability issues.

Clinical development plans and timelines

• A 28-day phase II obesity study is set to begin in early second half of the year, with data expected by early 2025, possibly sooner.

• A longer, three-month monotherapy study and a combination study with semaglutide are planned for early 2025.

• The oral NLRP3 inhibitor is positioned as a potential monotherapy, combination, or maintenance therapy, offering alternatives to injectable GLP-1s and aiming to avoid GI side effects.